Popping the Gross-to-Net Bubble, Part IV: Extreme Examples of Who Grew the Bubble
An exploration into how flawed incentives and contractual loopholes between manufacturers and pharmacy benefit managers played their part.
Reviewing the Most-Favored Nation Model
How practical is this form of pricing in the pharma setting?
